Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

While Spravato’s underlying mechanisms remain ... some critics continue to voice concerns about lingering long-term health questions and unregulated clinics. Licensed medical providers have ...

My two questions. First of all ... positive commentary on some of the newer drugs you've had, whether that's Spravato broadening or neffy coming out of the gate in 4Q, would you say that 2025 ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Spravato (esketamine ... In draft guidance, NICE says that there are questions about not only the price of the medicine – which costs around £10,500 per course of therapy ahead of any discounts ...

With SPRAVATO surpassing $1 billion in annual sales ... With that, we are happy to take your questions. So I will now turn it to Kevin to provide instructions for those seeking to participate ...

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.